The old adage, prostate cancer is the cancer that you die with not the cancer you die from has been around for a long time. No question compared too many other cancers prostate cancer does progress more slowly than many other cancers. But, is this adage true? Men with prostate cancer have competing mortality risks [...]
There has been a lot of criticism about the recent guidelines on PSA testing that has been issued by the American Cancer Society (ACS). Many of us with advanced prostate cancer are appalled with these guidelines and feel it is just another example of the ACS abandoning men with cancer over the powerful breast cancer [...]
The House Committee on Oversight and Government Reform, chaired by Congressman Edolphus Towns, will hold a hearing entitled: “Prostate Cancer: New Questions About Screening and Treatment” tomorrow, Thursday, March 4, 2010 at 10:00 a.m. This is the first Congressional prostate cancer hearing in 11 years and, in the midst of debate on a health reform [...]
A Gleason Score of 7 is often looked at as a middle range score, but clearly not as serious as an 8 or 9 score. Some recently combined research performed at the Department of Urology, University of Washington School of Public Health, Seattle, Washington and the Division of Public Health Sciences, Fred Hutchinson Cancer Research [...]
David P. Wood, Jr., MD gave a presentation at the 9th International Prostate Forum (IPF) on October 8 - 10, 2009 in Izmir, Turkey on the Management the side effects of hormone therapy (ADT) when used to treat of prostate cancer. Dr. Wood indicated that the three major side effects of ADT in the treatment [...]
One of the most heated debates in prostate cancer care is around the use of 5-reductase inhibitors (5ARI) like Dutasteride as a third component of a hormone blockade (ADT3). 5-ARIs block the conversion of testosterone to dihydrotestosterone (DHT). DHT is thought to be an extremely powerful “fuel” for the growth of prostate cancer. However, there [...]
A known fact is that between 15% to 35% of men who have surgery as their primary treatment after diagnosis of prostate cancer will experience a biochemical recurrence (BCR). The authors of a presentation, Michael B. Williams, MD, et al. presented at the American Urological Association Mid-Atlantic Section - 67th Annual Meeting - October 1 [...]
Concerned that your diabetes could making you more vulnerable to dying from prostate cancer? Yes, diabetes sufferers should be concerned about a potential shorter life span, but not as of a result of prostate cancer (CaP). In the Journal of Clinical Oncology (September 10, 2008), Dr. Matthew Smith and his colleagues reported on the association [...]
Confirming a belief of many of us, new research has found that hormone therapy (endocrine therapy or ADT) is associated with a very large increased risk of developing various major heart problems. This research also tells us that some therapy options have a higher risk profile than others. At Europe's biggest cancer congress, ECCO 15 [...]
Advanced prostate cancer will progress and most of us will face a time when Androgen Deprivation Therapy (ADT) stops working. Most men on ADT take a LHRH agonist, which turns off the production of testosterone (i.e. Lupron) along with a non-steroidal anti-androgen (i.e. Casodex) that prevents the small amount of testosterone that continues to be [...]
